Cerenome is trading at $2.00, up 6.95%, following its September 30 business update, which reported unaudited Q3 gross billings. - The update reported $1.55 million from 222 tests; initial cash collections are anticipated in Q4. It noted shares rose following the update. - It cited a favorable preliminary CMS pricing decision for code 0640U, targeted to take effect January 1, 2027. - Gross billings are not GAAP revenue and do not indicate amounts that will be collected.